Table 2 Correlation between disease activity and drug therapy (oETA and bETA) before switch and after switch, during 6 and 12 months of follow-up.

From: Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis

 

oETA Pre-Switch (M*- IQ)

bETA Bsl (M*- IQ)

bETA 6th (M*- IQ)

bETA 12th (M*- IQ)

oETA/bETA

Bsl (p-val)

oETA/bETA

6th (p-val)

oETA/bETA

12th (p-val)

bETA Bsl-6th (p-val)

bETA Bsl-12th (p-val)

bETA 6-12th (p-val)

RA (48 pts) DAS28

2.5 (1.8–4.8)

2.5 (1.9–4.7)

2.40 (1.8–7.8)

2.84 (1.8–4.7)

0,740

0,545

0,793

0,742

0,405

0,443

PsA (26 pts) DAPSA

10.0 (6.0–31.0)

7.0 (5.0–24.0)

10.5 (4.0–46.0)

14.9 (6.4–40.8)

0,461

0,506

0,598

1,000

0,205

0,231

AS (13 pts) BASDAI

1.7 (1.3–9.0)

2.0 (1.0–7.5)

2.55 (1.0–8.6)

1.75 (1.0–5.,6)

0,697

0,646

0,596

0,901

0,750

0,525

  1. RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing spondylitis, DAS28 Disease Activity Score 28, DAPSA Disease Activity in Psoriatic Arthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, M* median, IQ inter-quartile range, Bsl baseline, p-val p-value.
Back to article page